Other equities analysts have also issued reports about the company. Jefferies Group reaffirmed a buy rating on shares of Shire PLC in a research note on Friday, July 1st. Sanford C. Bernstein reissued an outperform rating and set a $222.00 price target on shares of Shire PLC in a research report on Thursday, June 9th. Royal Bank Of Canada reissued an outperform rating on shares of Shire PLC in a research report on Wednesday, June 15th. BTIG Research reissued a buy rating and set a $230.00 price target on shares of Shire PLC in a research report on Tuesday, July 12th. Finally, RBC Capital Markets reissued an outperform rating on shares of Shire PLC in a research report on Wednesday, August 3rd. Five research analysts have rated the stock with a hold rating and twenty-two have issued a buy rating to the company. The company has a consensus rating of Buy and an average target price of $232.75.
Shares of Shire PLC (NASDAQ:SHPG) opened at 193.86 on Wednesday. Shire PLC has a 12-month low of $147.60 and a 12-month high of $231.32. The firm has a market capitalization of $57.74 billion, a P/E ratio of 40.29 and a beta of 1.16. The stock has a 50 day moving average price of $196.13 and a 200 day moving average price of $185.72.
Shire PLC (NASDAQ:SHPG) last released its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share for the quarter, beating the consensus estimate of $3.03 by $0.35. The business had revenue of $2.43 million for the quarter, compared to analyst estimates of $2.28 billion. Shire PLC had a return on equity of 17.70% and a net margin of 13.19%. The company’s revenue was up 55.9% compared to the same quarter last year. During the same period in the previous year, the company posted $2.63 EPS. Equities analysts anticipate that Shire PLC will post $12.92 earnings per share for the current fiscal year.
The firm also recently declared a dividend, which will be paid on Friday, October 7th. Investors of record on Friday, September 9th will be given a dividend of $0.139 per share. The ex-dividend date of this dividend is Wednesday, September 7th. Shire PLC’s payout ratio is 15.63%.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Macquarie Group Ltd. acquired a new position in Shire PLC during the second quarter valued at $5,561,000. Northwestern Mutual Wealth Management Co. raised its position in Shire PLC by 157.9% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 8,645 shares of the biopharmaceutical company’s stock valued at $1,591,000 after buying an additional 5,293 shares during the last quarter. Cowen Group Inc. acquired a new position in Shire PLC during the second quarter valued at $920,000. Beacon Trust Co. acquired a new position in Shire PLC during the second quarter valued at $2,643,000. Finally, IFP Advisors Inc raised its position in Shire PLC by 871.9% in the second quarter. IFP Advisors Inc now owns 2,702 shares of the biopharmaceutical company’s stock valued at $497,000 after buying an additional 2,424 shares during the last quarter. 24.26% of the stock is currently owned by hedge funds and other institutional investors.
Shire PLC Company Profile
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.